Preactivated-thiolated polyacrylic acid/1-vinyl pyrrolidone nanoparticles as nicotine carriers for smoking cessation

Pornpitchanarong, Chaiyakarn; Rojanarata, Theerasak; Opanasopit, Praneet; Ngawhirunpat, Tanasait; Patrojanasophon, Prasopchai

doi:10.1039/d0ra06039a

Cited by 4 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The synthesis of PEGDA/AA NPs was accomplished by surfactant-free emulsion polymerization with different molar ratios of PEGDA and AA (0.5:1, 1:1, and 1:0.5) using a procedure modified from a previous report [ 25 ]. In brief, 100 mL of deionized water was placed in a clean round-bottomed flask and warmed to 70 °C while flushing with nitrogen.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Synthesis of Polyethylene Glycol Diacrylate/Acrylic Acid Nanoparticles as Nanocarriers for the Controlled Delivery of Doxorubicin to Colorectal Cancer Cells

et al. 2022

Self Cite

View full text Add to dashboard Cite

Doxorubicin (Dox) is known for its potential to deliver desirable anticancer effects against various types of cancer including colorectal cancer. However, the adverse effects are serious. This study aimed to synthesize polyethylene glycol diacrylate (PEGDA)/acrylic acid (AA)-based nanoparticles (PEGDA/AA NPs) for Dox delivery to colorectal cancer cells. The NPs were synthesized using free-radical polymerization reaction using the monomers PEGDA and AA with their physical properties, drug loading and release, biocompatibility, and anticancer effect evaluated. The NPs were spherical with a size of around 230 nm, with a 48% Dox loading efficiency and with loading capacity of 150 µg/mg. Intriguingly, the NPs had the ability to prolong the release of Dox in vitro over 24 h and were non-toxic to intestinal epithelial cells. Dox-loaded PEGDA/AA NPs (Dox-NPs) were able to effectively kill the colorectal cancer cell line (HT-29) with the Dox-NPs accumulating inside the cell and killing the cell through the apoptosis pathway. Overall, the synthesized PEGDA/AA NPs exhibit considerable potential as a drug delivery carrier for colon cancer-directed, staged-release therapy.

show abstract

Section: Methodsmentioning

confidence: 99%

“…The chemical shifts are given as parts per million (ppm). Additionally, the NPs were analyzed on an attenuated total reflection Fourier-transformed infrared (ATR-FTIR) spectrometer (Nicolet iS5, Thermo Scientific, Waltham, MA, USA) with 16 spectra collected between 400–4000 cm −1 with a resolution of 4.00 cm −1 [ 25 ].…”

Section: Methodsmentioning

confidence: 99%

Synthesis of Polyethylene Glycol Diacrylate/Acrylic Acid Nanoparticles as Nanocarriers for the Controlled Delivery of Doxorubicin to Colorectal Cancer Cells

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…These nanoparticles were shown to have superior mucoadhesion to porcine buccal mucosa when compared to thiolated and nonthiolated AA/VP nanoparticles. 246 The superior mucoadhesion compared to thiolated AA/VP nanoparticles was attributed to the increased stability of the nanoformulation as well as the increased availability of thiol groups to form disulfide linkages with mucin.…”

Section: Mucosae and Nanoparticle Designmentioning

confidence: 99%

Untangling Mucosal Drug Delivery: Engineering, Designing, and Testing Nanoparticles to Overcome the Mucus Barrier

Watchorn

Clasky

Prakash

et al. 2022

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Mucus is a complex viscoelastic gel and acts as a barrier covering much of the soft tissue in the human body. High vascularization and accessibility have motivated drug delivery to various mucosal surfaces; however, these benefits are hindered by the mucus layer. To overcome the mucus barrier, many nanomedicines have been developed, with the goal of improving the efficacy and bioavailability of drug payloads. Two major nanoparticle-based strategies have emerged to facilitate mucosal drug delivery, namely, mucoadhesion and mucopenetration. Generally, mucoadhesive nanoparticles promote interactions with mucus for immobilization and sustained drug release, whereas mucopenetrating nanoparticles diffuse through the mucus and enhance drug uptake. The choice of strategy depends on many factors pertaining to the structural and compositional characteristics of the target mucus and mucosa. While there have been promising results in preclinical studies, mucus−nanoparticle interactions remain poorly understood, thus limiting effective clinical translation. This article reviews nanomedicines designed with mucoadhesive or mucopenetrating properties for mucosal delivery, explores the influence of site-dependent physiological variation among mucosal surfaces on efficacy, transport, and bioavailability, and discusses the techniques and models used to investigate mucus−nanoparticle interactions. The effects of non-homeostatic perturbations on protein corona formation, mucus composition, and nanoparticle performance are discussed in the context of mucosal delivery. The complexity of the mucosal barrier necessitates consideration of the interplay between nanoparticle design, tissue-specific differences in mucus structure and composition, and homeostatic or disease-related changes to the mucus barrier to develop effective nanomedicines for mucosal delivery.

show abstract

Mucoadhesive forms

Khan,

Yadav,

Mehra

2025

Polymers for Oral Drug Delivery Technologies

View full text Add to dashboard Cite

Preactivated-thiolated polyacrylic acid/1-vinyl pyrrolidone nanoparticles as nicotine carriers for smoking cessation

Abstract: Preactivated-thiolated AA/VP NPs improved mucoadhesive property and prolonged nicotine release to 12 h.

Cited by 4 publications

References 39 publications

Synthesis of Polyethylene Glycol Diacrylate/Acrylic Acid Nanoparticles as Nanocarriers for the Controlled Delivery of Doxorubicin to Colorectal Cancer Cells

Synthesis of Polyethylene Glycol Diacrylate/Acrylic Acid Nanoparticles as Nanocarriers for the Controlled Delivery of Doxorubicin to Colorectal Cancer Cells

Untangling Mucosal Drug Delivery: Engineering, Designing, and Testing Nanoparticles to Overcome the Mucus Barrier

Mucoadhesive forms

Contact Info

Product

Resources

About